MetaCap

STAAR Surgical Company (STAA)

NASDAQ: STAAHealth CareOphthalmic GoodsUSD

24.22-0.81 (-3.24%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

STAA stock chart

Technical analysis

Key statistics

All statistics
P/E (TTM)
2,422.00
52-week range
15.59 – 35.87
Day range
23.87 – 25.08
Volume / Avg
585.63K / 835.89K
Beta
—

52-week range

$15.59$35.87

STAA stock today

On Nov 20, STAA ended the session at $24.22, shedding $0.81 (3.24%), versus the S&P 500's 3.70% decline. Shares are 32.5% below their 52-week high of $35.87, set on May 14, 2026 and 55.4% above the 52-week low of $15.59, in the middle of the past year's range. STAA is up 4.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 13.5%.

At 2,422x trailing earnings, STAAR Surgical's P/E ratio is unusually high because its trailing profit is very small relative to its share price.

Summary generated from market data by MetaCap's automated system. Methodology

About STAAR Surgical

Company profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists.

Industry
Ophthalmic Goods
CEO
Mr. Warren Foust
Headquarters
Lake Forest, CA
Employees
921
Website
staar.com

Financial highlights

Full financials

In fiscal 2025, STAAR Surgical generated $239.4 million in revenue, down 23.7% from fiscal 2024, its first annual decline since 2024. STAAR Surgical reported a net loss of $80.4 million, compared with a loss of $20.2 million a year earlier. Gross margin was 76.2% (down from 76.3%) and operating margin -38.3%.

STAAR Surgical annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$239.44M$313.90M$322.42M$239.44M$230.47M
Growth-23.72%-2.64%+34.65%+3.89%+41.00%
Net income$-80.45M$-20.21M$21.35M$39.66M$27.51M
EPS (diluted)$-1.62$-0.41$0.43$0.80$0.56

Analyst forecast

Forecast

Consensus (11 analysts)

buy

Avg. price target

$28.56+17.92%

  • Strong buy 0
  • Buy 4
  • Hold 6
  • Sell 1
  • Strong sell 0

Target range

Low $19.00High $37.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$0.11 vs $0.05
Surprise
+120.00%

STAA news

All STAA news

STAAR Surgical peers

Health Care sector
STAA peer companies
CompanyPrice% ChgMarket capCompare
EYENational Vision Holdings Inc.16.72-1.70%$1.31Bvs STAA
RXSTRxSight Inc.4.47-3.04%$187.42Mvs STAA
LUCYInnovative Eyewear Inc.0.7025-0.07%$6.12Mvs STAA
WRBYWarby Parker Inc. Class A23.12-4.19%$2.87Bvs STAA
BLCOBausch + Lomb Corporation19.38-6.33%$6.93Bvs STAA
COOThe Cooper Companies Inc.58.88-2.40%$11.20Bvs STAA
ALCAlcon Inc.74.31-0.26%$35.70Bvs STAA

Indexes, lists and sector

STAAR Surgical stock FAQ

What is STAAR Surgical's stock price today?

STAA last traded at $24.22 as of Nov 20, 4:00 PM EST, down 3.24% on the day. Prices are delayed at least 15 minutes.

Does STAAR Surgical pay a dividend?

No. STAAR Surgical does not currently pay a regular cash dividend.

What is STAA's P/E ratio?

STAA trades at a trailing P/E ratio of 2422.00 and a forward P/E of 21.39, compared with a median of 20.4 for its closest peers.

Who is STAAR Surgical's CEO?

Mr. Warren Foust is the chief executive officer of STAAR Surgical Company, which has about 921 employees.

Has STAA ever split its stock?

Yes. The most recent STAA stock split was a 1-for-2 split on May 18, 1992.

What is the STAA 52-week high?

The 52-week high for STAA is $35.87 and the 52-week low is $15.59. The stock is currently 32.5% below its high.

Compare STAA